Goodbye trial and error: how AI is rewriting the rules of drug discovery - Futura, le média qui explore le monde (opens in new tab)

By 2026, machine learning tools routinely reduce early discovery timelines by roughly a third. Preclinical candidate development has dropped from four years down to 13 to 18 months. Today, nearly one in three new drugs incorporates computational tools during early discovery. The technology has rapidly transitioned into standard industry infrastructure....